The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors
The biotech markets of early 2026 have become a theater of the extreme, where the…
Signals
Early signs, trends, and market shifts worth tracking.
Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction
The pharmaceutical sector has officially transitioned from cautious capital preservation to a state of aggressive,…
Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch
CRL Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch No fireworks. A 7:12…
Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours
At 9:15 a.m. Mumbai time, Nov. 6, 2015, a single document changed billions in market…
Nitrosamines 2.0: new AI thresholds, new “casualties,” and finally predictable rules
The story really does begin in a hot stretch of 2025, when three regulators –…
Unmet Opportunities: Analyzing the FDA List of Drugs Without Approved Generics
The FDA’s Off-Patent, Off-Exclusivity Drugs without an Approved Generic list highlights pharmaceutical products that are…